Contact
Search
Our Company
Leadership Team
Careers
Grants & Sponsorships
Expanded Access
Contact Us
Programs & Pipeline
Programs
Pipeline
Resources
For Patients & Providers
Mitochondria & Disease
Mitochondrial Diseases
Community
Contact Us
Scientific Data
Publications
Presentations
Investors & News
About
Stock Information
Reports & Filings
News
Publications
IR Presentations
Events
Corporate Governance
Contact Us
Reports
Email Alerts
Contact Us
Investors & News
Latest News
Apr 06,2021
Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights
Mar 31,2021
Stealth BioTherapeutics to Report Full Year 2020 Financial Results on Tuesday, April 6, 2021
Mar 16,2021
Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer
All News
Stock Quote (MITO)
Share
Why invest?
Our Company
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.
Our Programs
We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.
Our Pipeline
We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.
Latest Reports
April 07, 2021
Form 424B3 : Prospectus filed pursuant to Rule 424(b)(3)
HTML
April 06, 2021
Form 20-F : Annual and Transition Report (foreign private issuer)
HTML
Reports
Latest Presentations
March 05, 2021
Investor Presentation March 2021
February 18, 2020
Barth Syndrome Efficacy Study Using Natural History Data as a Control
Presentations
Events
April 06, 2021
Fiscal Year 2020 Financial Results and Business Highlights Conference Call
Webcast
March 17, 2021
Oppenheimer's 31st Annual Healthcare Conference at 10:40 am ET
Webcast
Financial Calendar
Media Relations
Amelia Stetler, 617-762-2562
media@stealthbt.com
Investor Inquiries
Stern IR
Janhavi Mohite, 212-362-1200
IR@stealthbt.com
